Zent2U is pleased to announce the successful EU registration of Sitagliptin phosphate + Metformin 50mg/1000 mg and 50mg/850 mg/ tablets. At the moment, the harmonized part of the registration procedure is finished, and national registration procedures are pending in order to obtain Marketing Authorization across European countries shortly. 🌍
Sitagliptin phosphate in combination with Metformin is indicated in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. 💊
Sitagliptin phosphate + Metformin Zent2U is a generic alternative to the medication Janumet® by Merck Sharp & Dohme B.V.®.
We are pleased to provide our partners with this new generic product, enhancing their portfolio of diabetes medication. 🤝
Partner up now and connect with our team today! 📧
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
Zent2U innovation HealthcareAdvancements diabetesmellitus B2B generics partnership
